Previous Speakers (2022 part 2)
Some seminars were recorded and accessible for a limited time on our youtube channel.
January 5th, 2023
Host: Katherine Donovan
Sai Gourisankar
Stanford University
Chemical Rewiring of Cancer Drivers to Activate Apoptosis
Sai Gourisankar is a PhD student in Gerald Crabtree’s laboratory at Stanford University. His studies developed chemical inducers of proximity to regulate endogenous chromatin and transcriptional regulators in genetically unmodified cells, using a combination of biochemical, genomic, and chemical approaches in collaboration with the laboratory of Nathanael Gray. Prior to joining Stanford in 2017 and studying chemical biology, Sai acquired an MPP from University of Oxford and originally obtained both a B.S. and a B.A. in Chemical Engineering and Liberal Arts from the University of Texas at Austin.
Xingui Liu
University of Dundee
Discovery of XL01126: a PROTAC degrader of Leucine Rich Repeat Kinase 2
Xingui is currently a Marie Skłodowska-Curie fellow in Prof. Alessio Ciulli’s lab at the Center for Targeted Protein Degradation (CeTPD), where she is focusing her research on developing PROTAC degraders of Leucine Rich Repeat Kinase 2 (LRRK2), a promising target for Parkinson’s disease. Before joining the Ciulli group, she was a Postdoc associate at the University of Florida working with Prof. Guangrong Zheng and Prof. Daohong Zhou. At the University of Florida, she was part of a team that developed very effective BCL-XL/BCL-2 PROTAC degrader molecules. One of which was licensed to the Dialectic Therapeutics and led to the development of one of the first VHL-based PROTACs to enter the clinic and to be dosed in human patients for the treatment of hematological malignancies. She completed her PhD in Guangrong Zheng’s lab at University of Arkansans for Medical Sciences, where she designed, synthesized, and characterized delta-tocotrienol based radio-protectors.
Link to the recorded seminar: https://youtu.be/v_GUzZeoYXg
January 19th, 2023
Host: Mikolaj Slabicki
Zuzanna Kozicka
FMI
Molecular glue degraders of cyclin K and the emerging rules for molecular glue design
Zuzanna is a very recent PhD graduate working in the laboratory of Nicolas Thomä at the Friedrich Miescher Institute in Basel, Switzerland. She has an avid interest in molecular glue degraders and, more generally, in understanding how changes in protein interactomes can be brought about by the binding of small molecules. Prior to joining the Thomä lab in late 2018, Zuzanna obtained an Integrated Masters degree from the University of Edinburgh and during her studies she undertook various research projects, including with Nenad Ban at ETH and with Alessio Ciulli at the University of Dundee.
Host: Radek Nowak
Breanna Zerfas
DFCI
HiBit-SpyTag: A minimal tag for covalent protein capture and degrader development.
Breanna Zerfas is currently the biochemistry and structural biology group leader and a senior scientist at the Center for Protein Degradation (CPD) in the Dana-Farber Cancer Institute. She received her PhD in chemical biology from Boston College in 2017, working with Prof. Jianmin Gao on the design and synthesis of unnatural peptide antibiotics. From there, Breanna moved to the Department of Medicinal Chemistry and Molecular Pharmacology at Purdue University as a post-doc with Prof. Darci Trader. While at Purdue, her research focused on the screening and development of fluorescence-based probes selective for various isoforms of the proteasome to be used in live cells. In the spring of 2020, Breanna moved back to Boston and joined the CPD, where her work primarily focuses on the development of new assays and chemical biology tools for target identification and high throughput screening.
February 2nd, 2023
Host: Breanna Zerfas
Behnam Nabet
Fred Hutchinson Cancer Center
Targeting kinases for destruction in cancer
Behnam Nabet, Ph.D. is an Assistant Professor in the Human Biology Division at Fred Hutchinson Cancer Center. He received his Ph.D. in Cancer Biology from Northwestern University and B.A. in Biology from the University of Pennsylvania. He performed his postdoctoral studies in the laboratories of Dr. Nathanael Gray and Dr. James Bradner at Dana-Farber Cancer Institute and Harvard Medical School. Dr. Nabet’s laboratory is focused on developing strategies to target oncogenic signaling by controlling protein homeostasis. He pioneered the development of a versatile technology platform known as the dTAG system to rapidly degrade any target protein. The dTAG system facilitates biological exploration and drug target validation in cells and animal models. Dr. Nabet’s work has led to the development of selective agents targeting several cancer drug targets including FAK, PIN1, and DCLK1. These promising compounds inhibit critical vulnerabilities in translational models of cancer and are under continued development as novel therapeutics. Dr. Nabet has been recognized with several scientific honors, including a Claudia Adams Barr Program for Innovative Cancer Research award, an American Cancer Society Postdoctoral Fellowship, a Katherine Loker Pinard Endowed Fellowship, and an NIH/NCI K22 Transition Career Development Award.
Frederick Cohen
Nurix Therapeutics
Discovery and Optimization of CBL-B Inhibitors
Fred Cohen is Head of Medicinal Chemistry at Nurix Therapeutics. He has more than 20 years of experience in small molecule drug discovery, spanning multiple therapeutic areas including oncology, neurodegeneration and antibiotics. Prior to joining Nurix, he served at Achaogen, Genentech, and Tularik. Dr. Cohen earned his bachelor’s degree in Chemistry from Occidental College and his Ph.D. in Chemistry from the University of California, Irvine.
%20(1).jpg)
February 16th, 2023
Host: Mikolaj Slabicki
Steve Elledge
Harvard Medical School
High through-put interrogation of the UPS
Stephen J. Elledge is the Gregor Mendel Professor of Genetics and Medicine at Harvard Medical School and the Brigham and Women’s Hospital Division of Genetics, and is a Howard Hughes Medical Institute Investigator. He received his B.S. in chemistry from the University of Illinois and his Ph.D. in biology from the Massachusetts Institute of Technology. He began his laboratory at the Baylor College of Medicine in Houston and moved in 2003 to the Brigham and Women’s Hospital and Harvard Medical School Department of Genetics. He is an elected member member of the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. His many awards include the Dickson Prize (2010), Lewis S. Rosenstiel Award for Distinguished Work in the Basic Medical Sciences (2013), Gairdner Foundation International Award (2013), Albert Lasker Basic Medical Research Award (2015), Breakthrough Prize in Life Sciences (2017) and the Gruber Prize in Genetics (2017).
Dr. Elledge’s research interests center on genetic approaches to biological problems including the study of proteins that sense and respond to DNA damage, and regulate the cell division cycle and cancer. Through this work he uncovered a protein kinase cascade that is now known as the DNA Damage Response. He discovered F-box proteins and Skp1 and along with Dr. Wade Harper, uncovered the two largest families of E3 ubiquitin ligases: the cullin-RING ligases (CRL), starting with the Skp1-Cul1-F-box sub-family, and the RING domain ligases. He has also worked in unraveling the role of cancer drivers in the evolution of cancer through aneuploidy and how tumor suppressors allow cancers to evade the immune system. More recently Dr. Elledge has developed a suite of immunological methods, such as T-Scan, VirScan and EpiScan, that allows the genome-wide identification of epitopes recognized by B and T cells. He has used these tools to investigate the role of viruses in human disease such as Measles, MS and COVID-19.
March 2nd, 2023
Host: Hojong Yoon / Radosław Nowak
John Gross
UCSF
RNA is a molecular glue that mediates HIV-1 Vif antagonism of human APOBEC3G
John Gross is a professor of Pharmaceutical Chemistry at UCSF. The Gross lab focuses on studying the control of mRNA decay and protein turnover in normal and virally infected cells. He received his PhD in Physical Chemistry at MIT, developing methods for biological solid-state NMR under the guidance of Professor Bob Griffin. Then he did his postdoctoral fellowship in Gerhard Wagner’s lab at Harvard Medical School, studying mRNA translation initiation, and joined the faculty of UCSF in 2004.
Link to the recorded seminar: https://youtu.be/q-b8K-UjZj4
Kanak Raina
Halda Therapeutics
Regulated Induced Proximity Targeting Chimera (RIPTACTM) Therapeutics: Chemical Biology Proof-of-Concept and Application in Prostate Cancer
Kanak Raina is a Director in the Biology Department at Halda Therapeutics. Dr. Raina received his PhD from the laboratory of Prof. Craig Crews at Yale University in 2014, where he worked on the manipulation of cellular proteostasis using small molecules. Following his PhD, Dr. Raina transitioned to drug discovery in the industry setting by moving to Arvinas, where he was biology lead on several exploratory pipeline TPD programs. Following a stint working on ER stress pathway inhibitors at Quentis Therapeutics, Dr. Raina moved to Halda in 2019, where he has been involved in the conceptualization of novel heterobifunctional small molecule therapeutics, and is leading biology efforts on the company's RIPTAC Therapeutic program for prostate cancer."
March 16th, 2023
Host: Breanna Zerfas / Radosław Nowak
Vincenzo D'Angiolella
Oxford Institute for Radiation Oncology
Neomorphic mutations in E3 ubiquitin ligases to divert substrate specificity
Vincenzo D’Angiolella is an Associate Professor at the Oxford Institute for Radiation Oncology. His research group focuses on understanding the role of the ubiquitin system in cancer pathogenesis and response to treatment with chemo- and radiotherapy. He is currently holding two programme grants from the Cancer Research UK (CRUK) and Medical Research Council (MRC), focused on the role of Cullin Ring ubiquitin Ligases (CRLs) in brain cancers (medulloblastoma and glioblastoma) pathogenesis. Studies from his laboratory have uncovered the mechanism of action and function of Fbxl17 in medulloblastoma (Raducu et al., 2016) and highlighted a novel synthetic lethal interaction between cyclin F loss and Chk1 kinase inhibition (Burdova et al., 2019). More recently, the laboratory has identified that mutations occurring on the E3 ligase KBTBD4 in medulloblastoma change substrate specificity driving the recognition of the chromatin remodelling complex CoREST (Chen et al., 2022). This work describes the first neomorphic mutation in an E3 ubiquitin ligase and elucidates a novel mechanism of tumorigenesis in medulloblastoma. Vincenzo has a Medical Degree (MD) from the University of Naples “Federico II” and completed his PhD at the same University in the field of General Pathology. During his PhD utilizing X. Laevis as a model system, he investigated the process of mitosis and spindle checkpoint (D'Angiolella et al., 2001; D'Angiolella et al., 2003; D'Angiolella et al., 2007) Following the completion of his studies, he worked as a postdoctoral fellow at the New York University School of Medicine in the USA in the laboratory of Professor Michele Pagano. During the postdoctoral studies, he elucidated the mechanism-of-action and function of cyclin F, the founding member of the F-box proteins. He uncovered that cyclin F does not partner with Cyclin Dependent Kinases (CDKs) like other cyclins do, but acts as an E3 ubiquitin ligase, forming a canonical CRL1 (D'Angiolella et al., 2012; D'Angiolella et al., 2010).
Link to the recorded seminar: https://youtu.be/VO0qT_hrgh8
Dongwen Lyu
UT Health
Discovery of novel covalent E3 ligase ligands for degrader design
Dr. Dongwen Lyu (Lv) is an Assistant Professor/Research in the department of Department of Biochemistry and Structural Biology at UT Health San Antonio. His current research addresses two broad topics. The first topic is to study the cellular and molecular mechanisms of aging and age-related diseases and discover new senolytic drugs which can selectively eliminate senescent cells to treat aging and age-related diseases. The second topic is to study the mechanism of cancers and develop small molecules including covalent and non-covalent inhibitors and proteolysis targeting chimeras (PROTACs) degraders to treat cancers. He has published 42 peer-reviewed papers. His work includes the development of the first-generation selective BCL-XL PROTAC degrader (DT2216) and the second-generation BCL-xL and BCL-2 dual-degrading PROTAC (753b). DT2216 is currently being investigated as a novel anticancer agent in a Phase-1 clinical trial at Dialectic Therapeutics. Most recently, he led an interdisciplinary team to build new assays for target identification and validation, and to discover new E3 ligase ligands to extend the frontiers of targeted protein degradation.
https://zheng.pharmacy.ufl.edu/
Link to the recorded seminar: https://youtu.be/G-mAz1x1sj8